They include: BRAF inhibitors such as vemurafenib and dabrafenib used alone or in combination with the mitogen-activated protein kinase (MEK) inhibitor like trametinib dedicated to patients with a BRAFV600 mutation (35–50% of melanoma) [4]. Here, BRAF is linked to melanoma.